Meet New England’s Newest Komen Scholars
The Komen Scholars are an advisory group of 60 distinguished scholars and leaders in breast cancer research and advocacy. Each has made significant contributions to advancing the field or demonstrated significant promise of doing so in the future and all are committed to furthering Susan G. Komen®’s mission. We welcomed 4 new Komen Scholars to the New England region in 2016:
Tari King, M.D., Dana-Farber Cancer Institute | Boston, MA
Surgery; detection & diagnosis; epidemiology; genetics & molecular biology; omics; primary prevention/ risk reduction; special populations
Dr. King is developing tools and strategies to provide comprehensive risk assessment, counseling, education and prevention for racially and economically diverse populations who may not otherwise seek these services.
Jennifer Ligibel, M.D., Dana-Farber Cancer Institute | Boston, MA
Oncology; behavioral sciences; complementary & integrative medicine; endocrinology; survivorship; physical activity; obesity; nutrition; biomarkers
Dr. Ligibel is studying whether weight loss can reduce the risk of breast cancer recurrence in women with early-stage breast cancer, through a randomized trial evaluating the impact of a supervised weight loss plus health education materials versus materials alone upon invasive disease free survival in overweight and obese women with Stage II-III breast cancer.
Kornelia Polyak, M.D., Ph.D., Dana-Farber Cancer Institute | Boston, MA
DCIS; tumor diversity; tumor microenvironment; tumor evolution; epigenetics; cancer metastasis; immune evasion
Dr. Polyak is exploring new approaches to breast cancer prevention by using transient treatment with TGFβ receptor inhibitor (TGFBRi), alone or in combination, to target specific luminal epithelial progenitors that have proliferative potential to create pre-cancerous lesions, and consequently decrease mammary tumor development.
Lajos Pusztai, M.D., D.Phil., Yale University | New Haven, CT
Oncology; cancer genomics; bioinformatics; clinical trial design; prognostic & predictive biomarkers
Dr. Pusztai’s work focuses on characterizing the immune microenvironment of primary breast cancer before and after preoperative chemotherapy and assess similarities and differences in the immune microenvironment of primary and metastatic samples from the same patient with the goal of better understanding what drives immune cell infiltration to improve tumor vaccination strategies.